Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $60.78 million. The enterprise value is -$44.83 million.
Important Dates
The last earnings date was Tuesday, March 18, 2025, before market open.
| Earnings Date | Mar 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 61.59 million shares outstanding. The number of shares has increased by 46.46% in one year.
| Current Share Class | 61.59M |
| Shares Outstanding | 61.59M |
| Shares Change (YoY) | +46.46% |
| Shares Change (QoQ) | +0.88% |
| Owned by Insiders (%) | 6.25% |
| Owned by Institutions (%) | 33.98% |
| Float | 44.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.84 |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.17.
| Current Ratio | 7.49 |
| Quick Ratio | 7.18 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.75% and return on invested capital (ROIC) is -28.46%.
| Return on Equity (ROE) | -62.75% |
| Return on Assets (ROA) | -24.77% |
| Return on Invested Capital (ROIC) | -28.46% |
| Return on Capital Employed (ROCE) | -47.00% |
| Revenue Per Employee | $366,955 |
| Profits Per Employee | -$1.76M |
| Employee Count | 44 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.76% in the last 52 weeks. The beta is 1.11, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -74.76% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 40.96 |
| Average Volume (20 Days) | 476,374 |
Short Selling Information
The latest short interest is 6.92 million, so 11.24% of the outstanding shares have been sold short.
| Short Interest | 6.92M |
| Short Previous Month | 7.01M |
| Short % of Shares Out | 11.24% |
| Short % of Float | 15.62% |
| Short Ratio (days to cover) | 10.22 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $16.15 million and -$77.33 million in losses. Loss per share was -$1.32.
| Revenue | 16.15M |
| Gross Profit | 15.67M |
| Operating Income | -65.57M |
| Pretax Income | -57.80M |
| Net Income | -77.33M |
| EBITDA | -62.59M |
| EBIT | -65.57M |
| Loss Per Share | -$1.32 |
Full Income StatementBalance Sheet
The company has $126.93 million in cash and $20.20 million in debt, giving a net cash position of $106.73 million or $1.73 per share.
| Cash & Cash Equivalents | 126.93M |
| Total Debt | 20.20M |
| Net Cash | 106.73M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 120.75M |
| Book Value Per Share | 2.01 |
| Working Capital | 114.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$57.67 million and capital expenditures -$237,000, giving a free cash flow of -$57.91 million.
| Operating Cash Flow | -57.67M |
| Capital Expenditures | -237,000 |
| Free Cash Flow | -57.91M |
| FCF Per Share | -$0.94 |
Full Cash Flow StatementMargins
| Gross Margin | 97.06% |
| Operating Margin | -406.11% |
| Pretax Margin | -492.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.46% |
| Shareholder Yield | -46.46% |
| Earnings Yield | -124.93% |
| FCF Yield | -93.55% |
Analyst Forecast
The average price target for Pyxis Oncology is $9.20, which is 832.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.20 |
| Price Target Difference | 832.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 38.66% |
| EPS Growth Forecast (5Y) | -2.93% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -0.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.27 |
| Piotroski F-Score | 2 |